Pharmacokinetics, biodistribution and dosimetry of 99mTc labeled anti-human epidermal growth factor receptor humanized monoclonal antibody R3 in rats

Nuclear Medicine and Biology

Volumn 25, Issue 1, 1998, Pages 17-23

  Iznaga Escobar, Normando ^a   Morales Morales, Alejo ^a   Ducongé, Jorge ^b   Caballero Torres, Idania ^a   Fernández, Eduardo ^b   Gómez, José A ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b UNIVERSITY OF HAVANA   (Cuba)

Author keywords

Anti hEGF r humanized antibody; Biodistribution; Dosimetry; Pharmacokinetics; Radiolabeling

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; HUMAN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY TC 99M;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DOSIMETRY; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG TISSUE LEVEL; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PHARMACOKINETICS; RADIATION DOSE; RAT;

ANIMALS; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOCONJUGATES; ISOTOPE LABELING; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RATS; RATS, WISTAR; RECEPTOR, EPIDERMAL GROWTH FACTOR; TECHNETIUM COMPOUNDS; TISSUE DISTRIBUTION;

EID: 0031986186     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(97)00139-X     Document Type: Article

References (37)

1. 1. Akaike A. (1978) Posterior probabilities for choosing regression model. Ann. Inst. Math. Stat. 30, A9-A14.
2. 2. Cohen S., Fava R. A. and Sawyer S. T. (1982) Purification and characterization of epidermal growth factor receptor/protein kinase from normal mouse liver. Proc. Natl. Acad. Sci. USA 79, 6237-6241.
3. 3. Cohen S., Ushiro N., Stoscheck C. and Chinkers M. (1982) A native 170,000 epidermal growth factor receptor-kinase complex from shed plasma membrane vesicles. J. Biol. Chem. 257, 1523-1531.
4. 4. Divgi C. R., Welt S., Kris M., Real F. X., Yeh S. D. J., Gralla R., Merchant B., Schweighart S., Unger M., Larson S. M. and Mendelsohn J. (1991) Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J. Natl. Cancer Inst. 83, 97-104.
5. 5. Fernández A., Pérez R., Macias A., Velandia A., Alvarez I., Ramos M. and Velozo A. (1989) Generación y caracterización primaria de anticuerpos monoclonales contra el receptor del factor de crecimiento epidérmico. Interferón Biotecnología 6, 289-299.
6. 6. Fernández A., Spitzer E., Pérez R., Boehmer F. D., Eckert K., Zschiesche W. and Grosse R. (1992) A new monoclonal antibody for detection of EGF-receptors in Western blots and paraffin-embedded tissue sections. J. Cell. Biochem. 49, 157-165.
7. 7. Gibaldi M. and Perrier D. (1982) Pharmacokinetics. In: Pharmacokinetics, 2nd ed. (Edited by Gibaldi M. and Perrier D.), pp. 319-355. Marcel Dekker, New York.
8. 8. Iznaga Escobar N., Morales A. and Núñez G. (1996) Micromethod for quantification of SH groups generated after reduction of monoclonal antibodies. J. Nucl. Med. Biol. 23, 641-644.
9. 99mTc-labeled anti-human epidermal growth factor receptor antibody (ior egf/r3) in patients with tumor from epithelial origin. I. Pharmacokinetics and clearances. J. Nucl. Med. 37 (in press).
10. 10. Jennrich R. Y. and Sampson P. F. (1968) Application of stepwise regression to nonlinear least squares estimation. Techometrics 10, 63-72.
11. 11. Jones P. T., Dear P. H., Foote J., Neuberger M. S. and Winter G. (1986) Replacing the complementary-determining regions m a human antibody with those from a mouse. Nature 321, 522-525.
12. 131I-19-iodocholesterol: The pitfalls of using tissue concentration data: The author's reply. J. Nucl. Med. 16, 248-249.
13. 131I-labeled p97-specific Fab fragments in human melanoma as a basis for radiotherapy. J. Clin. Invest. 72, 2101-2114.
14. 14. Loevinger R. and Berman M. (1976) MIRD Pamphlet No. 1, Revised. Society of Nuclear Medicine, New York.
15. 15. Loevinger R., Budinger T. F. and Watson E. E. (1988) MIRD Primer for Absorbed Dose Calculations. Society of Nuclear Medicine, New York.
16. 16. Macias A., Pérez R. and Lage A. (1985) Estudios sobre el factor de crecimiento epidérmico. II. Desarrollo de un radio-receptor análisis para la determinación de cantidades picomolares. Interferón Biotecnología 2, 115-127.
17. 17. Magnusson I., Rosen A. V., Nilsson R., Macias A., Pérez R. and Skoog L. (1989) Receptors for epidermal growth factor and sex steroid hormones in human colorectal carcinomas. Anticancer Res. 9, 299-302.
18. 18. Mateo C., Moreno E., Amour K., Lombardero J., Harris W. and Pérez R. (1997) Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: Recovery of antagonistic activity. Immunotechnology 3, 71-81.
19. 19. Miller R. A., Oseroff A. R., Strafte P. T. and Levy R. (1983) Monoclonal antibody therapeutic trials in seven patients with T-cell lymphoma. Blood 62, 988-995.
20. 20. Neal D. E., March C., Benett M. K., Abel P. D., Hall R. R., Sainsbury J. R. C. and Harris A. L. (1985) Epidermal growth factor receptors in human bladder cancer: Comparison of invasive and superficial tumors. Lancet 1, 346-348.
21. 21. Pérez R., Pascual M. R., Macias A. and Lage A. (1984) Epidermal growth factor receptors in human breast cancer. Breast Cancer Res. Treat. 4, 189-193.
22. 22. Rios M. A., Fernández A., Tormo B. R., Quintero S., Pérez I., Skoog L. and Pérez R. (1992) Heterogeneous expression of the EGF-receptor in human breast carcinoma. Anticancer Res. 12, 205-208.
23. 23. Schubiger P. A., Alberto R. and Smith A. (1996) Vehicles, chelators, and radionuclides: Choosing "building blocks" of an effective therapeutic radioimmunoconjugate. Bioconj. Chem. 7, 165-179.
24. 24. Snelling L., Miyamoto C. T., Bender H., Brady L. W., Steplewski Z., Class R., Emnch J. and Rackover M. (1995) Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas. Hybridoma 14, 111-114.
25. 25. Snyder W. S., Ford M. R., Warmer G. G. and Fisher H. L. (1978) Estimates of absorbed fractions for monoenergetic photon sources uniformly distributed in various organs of a heterogeneous phantom. In: Medical Internal Radiation Dose (MIRD). (Edited by The Society of Nuclear Medicine), pp. 50-67. Society of Nuclear Medicine, New York.
26. 26. Snyder W. S., Ford M. R., Warmer G. G. and Watson S. B. (1975) "S" absorbed dose per unit cumulated activity for selected radionuclides and organs. MIRD Pamphlet, No. 11. Society of Nuclear Medicine, New York.
27. 27. Stabin M. G. (1995) Patient dose from diagnostic and therapeutic radiopharmaceuticals. In: Internal Radiation Dosimetry: Health Physics Society 1994 Summer School (Edited by Raabe OG), pp. 375-392. Medical Physics Publishing, Madison, Wisconsin.
28. 28. Tempest P. R., Bremmer P., Lambert M., Taylor G., Furze J. M., Carr F. J. and Harris W. J. (1991) Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo. Biotechnology 9, 266-271.
29. 99mTc-human serum albumin. J. Nucl. Med. 19, 796-803.
30. 30. Veale D., Ashcroft T., March C., Gibson G. J. and Harris A. L. (1987) Epidermal growth factor receptors in non-small cell lung cancer. Br. J. Cancer 55, 513-516.
31. 31. Verhoeyen M., Milstein C. and Winter G. (1988) Reshaping human antibodies: Grafting an antilysozyme activity. Science 239, 1534-1536.
32. 32. Wawrzynczak E. J., Cumber A. J., Parnell G. D., Jones P. T. and Winter G. (1992) Blood clearance in rat of a recombinant mouse monoclonal antibody lacking the N-linked oligosaccharide side chains of the CH2 domains. Mol Immunol. 29, 213-220.
33. 33. Wawrzynczak E. J., Denham S., Parnell G. D., Cumber A. J., Jones P. T. and Winter G. (1992) Recombinant mouse monoclonal antibodies with single amino acid substitutions affecting Clq and high affinity receptor binding have identical serum half-lives in the BALB/c mouse. Mol. Immunol. 29, 221-227.
34. 34. Webster W. B., Harwood S. J., Carroll R. G. and Morrissey M. A. (1992) Pharmacokinetics of indium-111-labeled B72.3 monoclonal antibody in colorectal cancer patients. J. Nucl. Med. 33, 498-504.
35. 35. Yamaoka K., Nakagawa T. and Uno T. (1978) A nonlinear multiple regression program, MULT(2) (Bayes), based on a Baye(s) algorithm for microcomputers. J. Pharmacobiol. Dyn. 8, 246-256.
36. 36. Yamaoka K., Nakagawa T. and Uno T. (1978) Application of Akaike's information criterion (AlC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6, 165-175.
37. 37. Yamaoka K., Nakagawa T. and Uno T. (1978) Statistical moments in pharmacokinetics. J. Pharmacokin. Biopharm. 6, 547-558.